Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Bicalutamide is marketed in Australia as Bicalide, Bicalox and Calutex, among others.
Metastatic (stage D) carcinoma of the prostate Clinical criteria: The treatment must be in combination with GnRH (LH-RH) analogue therapy.
“Bicalutamide is a non-steroidal anti-androgen, devoid of other endocrine activity. It binds to androgen receptors without activating gene expression, and thus inhibits the androgen stimulus.”
“The (S)-enantiomer is rapidly cleared relative to the (R)-enantiomer, the latter having a plasma elimination half-life of about 1 week.”
A plain-language summary of the cited sources below. Informational only — not medical advice.
Bicalutamide — Clinical Summary for Prescribers
Class / mechanism: Bicalutamide is a non-steroidal anti-androgen with no other endocrine activity. It binds androgen receptors without activating gene expression, thereby inhibiting the androgen stimulus.
Pharmacokinetics: Single-dose half-life is approximately 5.8 days; with continuous dosing, 7–10 days. The (S)-enantiomer is rapidly cleared, while the (R)-enantiomer has a plasma elimination half-life of about 1 week.
CYP/metabolic profile: In vitro,
Bicalutamide is marketed in Australia as Bicalide, Bicalox and Calutex, among others.
6 brand names are recorded against this substance from the TGA eBS Product Information repository. The full list is in the Also known as card.
Curated subset. The full adverse-effect list is in the TGA Product Information; click any citation above to open it.
“In vitro studies have shown that R-bicalutamide is an inhibitor of CYP 3A4, with lesser inhibitory effects on CYP 2C9, 2C19 and 2D6 activity.”